

### Clinical Policy: Obstetrical Home Care Programs

Reference Number: LA.CP.MP.91

Date of Last Review: 1/24

Revision Log
Coding Implications

See <u>Important Reminder</u> at the end of this policy for important regulatory and legal information.

#### **Description**

Medical necessity criteria for obstetrical home health programs offered by vendors such as Optum.

#### Policy/Criteria

**I.** It is the policy of Louisiana Healthcare Connections that obstetrical home health services are **medically necessary** for members/enrollees meeting the following criteria:

A.	Obstetrical Nurse Assessment	1
	Metoclopramide or Ondansetron Infusion Therapy	
	Hydration Therapy – one to four liters	
	Diabetes in Pregnancy Clinical Management Program (case rate)	
	Obstetrical Diabetes Management - Daily Insulin Injections or Insulin Pump	
	Hypertensive Disorders in Pregnancy Program for Gestational Hypertension	
	Hypertensive Disorders in Pregnancy Program for Preeclampsia	
	Preterm Labor Management Program	
	Dietary Analysis	

#### A. Obstetrical Nurse Assessment

An obstetrical nurse assessment is considered **medically necessary** when provided with any of the services listed in B to J.

B. Metoclopramide or Ondansetron Infusion Therapy

Home visits are considered **medically necessary** for the same period as the infusion therapy is administered, generally up to seven days of therapy based on clinical information.

C. Hydration Therapy – one to four liters

Hydration therapy is **medically necessary** for members/enrollees who could benefit from close surveillance for the onset of dehydration. Examples of diagnoses include:

- 1. Hyperemesis gravidarum;
- 2. Malabsorption;
- 3. Diagnosis, such as flu or GI virus, which impairs the member/enrollee's ability to maintain fluid and/or food in the system.

A course of up to seven days at a time is considered medically necessary.



D. Diabetes in Pregnancy Clinical Management

Diabetes in pregnancy clinical management is **medically necessary** for pregnant members/enrollees with a diagnosis of Type II non-insulin dependent diabetes in pregnancy, or non-insulin dependent gestational diabetes.

One visit is considered medically necessary for diabetes in pregnancy clinical management.

E. Obstetrical Diabetes Management - Daily Insulin Injections or Insulin pump
Obstetrical diabetes management is **medically necessary** for pregnant members/enrollees requiring insulin administration.

An initial course of up to seven days is considered medically necessary. Additional courses of up to seven-day spans are considered medically necessary until the member/enrollee is able to self-manage blood sugar and insulin administration.

- F. Hypertensive Disorders in Pregnancy Management for Gestational Hypertension Home visits for management of gestational hypertension are **medically necessary** for members/enrollees with one of the following:
  - 1. Elevated or unstable blood pressure without proteinuria;
  - 2. Member/enrollee who could benefit from education and surveillance for the potential onset of hypertension. Categories of such members/enrollees could include:
    - a. Previous episode of hypertension during previous pregnancy;
    - b. Chronic hypertension;
    - c. Multiple gestation;
    - d. Diabetes.

An initial visit is considered medically necessary.

- G. Hypertensive Disorders in Pregnancy Management for Preeclampsia
  Home visits for management of preeclampsia are **medically necessary** for pregnant
  members/enrollees who are diagnosed with preeclampsia without severe features,
  meeting all of the following:
  - 1. Blood pressure ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic on two occasions at least four hours apart after 20 weeks gestation in a member/enrollee with a previously normal blood pressure;
  - 2. Proteinuria demonstrated by one or more of the following:
    - a.  $\geq$  300 mg per 24-hour urine collection (or this amount extrapolated from a timed collection);
    - b. Protein/creatinine ratio  $\geq 0.3$  mg;
    - c. Dipstick reading of  $\geq 2+$  (30 mg/dL) (used only if other quantitative methods not available).

An initial home visit, with additional phone or virtual follow up as needed, is considered medically necessary.



#### H. Preterm Labor Management Program

The preterm labor management program is **medically necessary** for pregnant members/enrollees diagnosed with preterm labor. Early signs and symptoms of preterm labor can include menstrual-like cramping; mild, irregular contractions; low back ache; pressure sensation in the vagina; or vaginal discharge of mucus, which may be clear, pink, or slightly bloody.

An initial home visit, with additional virtual follow up as needed, is considered medically necessary for assessment and education. Ongoing visits are considered not medically necessary.

#### I. Dietary Analysis

A dietary analysis is **medically necessary** for members/enrollees with a diagnosis of obesity or malnutrition.

- **II.** It is the policy of Louisiana Healthcare Connections that the following services provided by a home health vendor are considered **not medically necessary**:
  - A. Betamethasone therapy via multiple repeat courses or intermittent injections;
  - B. Multiple gestation management (refer to individual program for identified risk factor);
  - C. Continuous heparin infusion therapy;
  - D. Member/enrollee-administered nonstress test or fetal heart rate monitoring;
  - E. Gestational diabetes clinical management program for oral medications;
  - F. Preterm prelabor rupture of membranes (PPROM) management.

#### **Background**

Optum Obstetrical (OB) Homecare includes risk assessment and education for identifying pregnant individuals at risk for complications, case management and homecare services for high-risk pregnancies. Obstetrical homecare services include providers, diagnostics, devices, and timely and actionable information that help individuals make better healthcare decisions.

#### Medically Necessary Services:

Diabetes in Pregnancy Clinical Management

In the United States, the two-step test is the most widely used approach for identifying pregnant people with gestational diabetes mellitus (GDM). The test is endorsed by America College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) considers it an acceptable option.<sup>10</sup>

The first step of the test is a one-hour 50-gram oral GTT administered without regard to time of day/previous meals. This step has a practical advantage since fasting is not necessary and only one blood sample is required. After step one, screen-positive individuals, except for those with very high glucose values, go on to the second step of the test which consists of a three-hour 100-gram oral GTT performed after an overnight fast.<sup>10</sup>

#### Gestational Hypertension Management

The American College of Obstetricians and Gynecologists (ACOG) Task Force on Hypertension in Pregnancy recommends that patients with gestational hypertension or preeclampsia without severe features monitor blood pressure twice weekly, self-monitor fetal movement daily, and



have platelet counts and liver enzymes assessed weekly.<sup>2</sup> Few studies have evaluated whether outpatient care is a viable option for preeclamptic patients, although two small studies found positive results.<sup>18</sup> In addition, a systematic review of three studies found no difference in clinical outcomes for mothers or babies receiving care in antenatal day units versus inpatient care.<sup>12</sup> ACOG recommends ambulatory management at home as an option for those with gestational hypertension or preeclampsia without severe features requiring frequent fetal and maternal evaluation. Hospitalization is recommended for individuals with severe features and for individuals in whom adherence to frequent evaluation may be a concern.<sup>22</sup>

#### Preterm Labor Management

There is little research on the management of patients after an episode of preterm labor. One underpowered study found no benefit to hospital care versus discharge home in the proportion of deliveries ≥36 weeks. It is thus recommended that the decision to manage an individual with preterm labor as an inpatient or outpatient should be made on a case-by-case basis, in conjunction with factors such as cervical dilation, vaginal bleeding, fetal status and travel time to the appropriate level of care facility.<sup>7</sup>

#### Not Medically Necessary Services:

Betamethasone therapy via intermittent injections

ACOG recommends a single course of corticosteroids for individuals with preterm premature rupture of membranes (PPROM) between 22 and 34 weeks, as it reduces the risk of neonatal mortality, respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis. However, ACOG does not recommend multiple repeated injections as weekly administration is associated with lower birthweight and head circumference. A Cochrane metareview of repeat doses of antenatal corticosteroids states that there was lower incidence of respiratory distress and serious infant health problems in the first few weeks after birth, but no evidence of harm or benefit in early childhood. Furthermore, as ACOG noted, repeat doses of corticosteroids were associated with lower birthweight and head circumference, even though these reductions were small. Crowther and colleagues conclude by recommending further research on the long-term benefits and risks of repeat doses of antenatal corticosteroids for the infant into adulthood. 11,15

#### Preterm Prelabor Rupture of Membranes Management

A Cochrane systematic review of two small studies concludes that the majority of patients should be managed in the hospital after PPROM.<sup>1</sup> Although the two studies suggest that outcomes are similar between individuals and babies managed at home or inpatient, the evidence is not sufficient to make a recommendation regarding the safety of home care for PPROM.<sup>1</sup> An additional small study of 187 patients with PPROM indicated conventional hospitalization as the treatment of choice when compared to home management especially in the presence of PPROM before 26 weeks, non-cephalic fetal presentation and oligoamnios.<sup>27</sup> ACOG sites the Cochrane review and also notes that the evidence is insufficient, adding that the increased risk of sudden infection and umbilical cord compression with PPROM make hospital surveillance the appropriate management choice.<sup>4</sup>

#### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted



2022, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

NOTE: Coverage is subject to each requested code's inclusion on the corresponding LDH fee schedule. Non-covered codes are denoted (\*) and are reviewed for Medical Necessity for members under 21 years of age on a per case basis.

ICD-10-CM	Description		
Codes			
A09	Infectious gastroenteritis and colitis, unspecified		
D69.59	Other secondary thrombocytopenia		
E86.0	Dehydration		
K90.49	Malabsorption due to intolerance, not elsewhere classified		
O10.011 through	Pre-existing essential hypertension complicating pregnancy		
O10.019			
O10.411 through	Pre-existing secondary hypertension complicating pregnancy		
O01.419			
O10.911 through	Unspecified pre-existing hypertension complicating pregnancy		
O10.919			
O11.1 through	Pre-existing hypertension with pre-eclampsia		
O11.9			
O14.00 through	Mild to moderate pre-eclampsia		
O14.03			
O16.1 through	Unspecified maternal hypertension		
O16.9			
O21.0 through	Excessive vomiting in pregnancy		
O21.9			
O24.410 through	Gestational diabetes mellitus in pregnancy		
O24.419			
O25.10 through	Malnutrition in pregnancy		
O25.13			
O60.00 through	Preterm labor without delivery		
O60.03			
O99.210 through	Obesity complicating pregnancy		
O99.213			

HCPCS Codes	Optum specific program codes
S9123	Nursing care, in the home; by registered nurse, per hour (use for general
	nursing care only, not to be used when CPT codes 99500-99602 can be used)



HCPCS	Optum specific program codes		
Codes	Optum specific program codes		
S9124 Nursing care, in the home; by licensed practical nurse, per hour			
S9140* Diabetic management program, follow up-visit to non-MD provider			
S9141*	Diabetic management program, follow-up visit to MD provider		
S9208*	Home management of preterm labor, including administrative services,		
39200	professional pharmacy services, care coordination, and all necessary supplies		
	and equipment (drugs and nursing visits coded separately), per diem (do not		
	use this code with any home infusion per diem code)		
S9209*	Home management of preterm premature rupture of membranes (PPROM),		
37207	including administrative services, professional pharmacy services, care		
	coordination, and all necessary supplies or equipment (drugs and nursing visits		
	coded separately), per diem (do not use this code with any home infusion per		
	diem code)		
S9211*	Home management of gestational hypertension, includes administrative		
57211	services, professional pharmacy services, care coordination and all necessary		
	supplies and equipment (drugs and nursing visits coded separately); per diem		
	(do not use this code with any home infusion per diem code)		
S9212*	Home management of postpartum hypertension, includes administrative		
57212	services, professional pharmacy services, care coordination, and all necessary		
	supplies and equipment (drugs and nursing visits coded separately), per diem		
	(do not use this code with any home infusion per diem code)		
S9213*	Home management of preeclampsia, includes administrative services,		
5,213	professional pharmacy services, care coordination, and all necessary supplies		
	and equipment (drugs and nursing visits coded separately); per diem (do not		
	use this code with any home infusion per diem code)		
S9214*	Home management of gestational diabetes, includes administrative services,		
D)21.	professional pharmacy services, care coordination, and all necessary supplies		
	and equipment (drugs and nursing visits coded separately); per diem (do not		
	use this code with any home infusion per diem code)		
S9374*	Home infusion therapy, hydration therapy; one liter per day, administrative		
	services, professional pharmacy services, care coordination, and all necessary		
	supplies and equipment (drugs and nursing visits coded separately), ); per		
	diem		
S9375*	Home infusion therapy, hydration therapy; more than one liter but no more		
	than two liters per day, administrative services, professional pharmacy		
	services, care coordination, and all necessary supplies and equipment (drugs		
	and nursing visits coded separately), per diem		
S9376*	Home infusion therapy, hydration therapy; more than two liters but no more		
	than three liters per day, administrative services, professional pharmacy		
	services, care coordination, and all necessary supplies and equipment (drugs		
	and nursing visits coded separately), per diem		
S9377*	Home infusion therapy, hydration therapy; more than three liters per day,		
	administrative services, professional pharmacy services, care coordination,		
	and all necessary supplies (drugs and nursing visits coded separately), per		
	diem		



HCPCS	Optum specific program codes
Codes	
S9470*	Nutritional counseling, dietitian visit
S9560*	Home injectable therapy; hormonal therapy (e.g., leuprolide, goserelin),
	including administrative services, professional pharmacy services, care
	coordination, and all necessary supplies and equipment (drugs and nursing
	visits coded separately), per diem

Reviews, Revisions, and Approvals		Approval Date
Converted corporate to local policy.	Date 12/1/202 0	Date
Annual review. Updated table of contents. Corrected A. to state that it is medically necessary with services in A-J, not A-K. References reviewed and updated. Specialist review. Changed "Last Review Date" in the header to "Date of Last Review" and "Date" in revision log to "Revision Date". Added "and may not support medical necessity" to coding implications. Added info in Background regarding ACOG's Statement on FDA Proposal to Withdraw 17p Hydroxyprogesterone Caproate. Note added to HCPCS S9123 regarding CPT usage.	2/22	
Annual review completed. Added "without proteinuria" to I. F.1.Changed "woman" to "member/enrollee" in I.G.1. Added "demonstrated by one or more of the following" to I.G.2. for clarity. Added "≥" to I.G.2.c. Minor rewording with no clinical significance. Background updated. References reviewed and updated. Removed references to CP.PHAR.14 in I.J. due to MCO manual- The MCO shall cover 17-alpha hydroxyprogesterone caproate (17P) without the requirement of prior authorization when substantiated by an appropriate diagnosis and all of the following criteria are met: $\varpi$ Current pregnancy with a history of pre-term delivery before 37 weeks gestation; $\varpi$ No symptoms of pre-term in the current pregnancy; $\varpi$ Current singleton pregnancy; and $\varpi$ Treatment initiation between 16 weeks 0 days and 23 weeks 6 days gestation	1/23	4/10/23
Removed references to CP.MP.34 Hyperemesis Gravidarum Treatment in I.B. and modified statement to reflect that home visits are medically necessary for the ondansetron/metoclopramide infusion administration period. Removed criteria J. for hydroxyprogesterone caproate (Makena) administration nursing visits.	4/23	7/21/23
Annual review. Updated Background with no impact to criteria. Updated version for inclusivity. References reviewed and updated. Added note for non-covered codes.	1/24	3/25/24

### References

1. Abou El Senoun G, Dowswell T, Mousa HA. Planned home versus hospital care for preterm prelabor rupture of the membranes (PPROM) prior to 37 weeks' gestation. *Cochrane* 



- *Database Syst Rev.* 2014;(4):CD008053. Published 2014 Apr 14. doi:10.1002/14651858.CD008053.pub3
- 2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013;122(5):1122 to 1131. doi:10.1097/01.AOG.0000437382.03963.88
- 3. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol*. 2018;131(2):e49 to e64. doi:10.1097/AOG.0000000000000501
- 4. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217. *Obstet Gynecol*. 2020;135(3):e80 to e97. doi:10.1097/AOG.0000000000003700
- American Diabetes Association. Standards of Medical Care in Diabetes 2018. *Diabetes Care*. Cefalu, WT (Ed.). January 2018; 41 (Supplement 1): S152 to 153. <a href="http://care.diabetesjournals.org/content/41/Supplement\_1/S152">http://care.diabetesjournals.org/content/41/Supplement\_1/S152</a> Accessed September 29, 2023.
- 6. August P, Sibai BM. Preeclampsia: Clinical features and diagnosis. UpToDate. <a href="https://www.uptodate.com">www.uptodate.com</a>. Updated June 6, 2023. Accessed September 29, 2023.
- 7. Caritis S, Simhan HN. Management of pregnant women after resolution of an episode of acute idiopathic preterm labor. UpToDate. <a href="www.uptodate.com">www.uptodate.com</a>. Updated April 4, 2023. Accessed September 29, 2023.
- 8. Durnwald C. Gestational diabetes mellitus: Glycemic control and maternal prognosis. UpToDate. <a href="https://www.uptodate.com">www.uptodate.com</a>. Updated June 19, 2023. Accessed September 29, 2023.
- 9. Caughey, AB. Gestational diabetes mellitus: Obstetrical issues and management. UpToDate. <a href="https://www.uptodate.com">www.uptodate.com</a>. Updated April 27, 2023. Accessed September 29, 2023.
- 10. Dumwald C. Gestational diabetes mellitus: Screening, diagnosis, and prevention. UpToDate. www.uptodate.com. Updated July 5, 2023. Accessed September 29, 2023.
- 11. Walters A, McKinlay C, Middleton P, Harding JE, Crowther CA. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. *Cochrane Database Syst Rev.* 2022;4(4):CD003935. Published 2022 Apr 4. doi:10.1002/14651858.CD003935.pub5
- 12. Dowswell T, Middleton P, Weeks A. Antenatal day care units versus hospital admission for women with complicated pregnancy. *Cochrane Database Syst Rev*. 2009;2009(4):CD001803. Published 2009 Oct 7. doi:10.1002/14651858.CD001803.pub2
- 13. Gupta Y, Kalra B, Baruah MP, Singla R, Kalra S. Updated guidelines on screening for gestational diabetes. *Int J Womens Health*. 2015;7:539 to 550. Published 2015 May 19. doi:10.2147/IJWH.S82046
- 14. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med*. 2008;358(19):1991 to 2002. doi:10.1056/NEJMoa0707943
- 15. Lee M-J, Guinn D. Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery. UpToDate. <a href="www.uptodate.com">www.uptodate.com</a>. Updated April 4, 2023. Accessed September 29, 2023.
- 16. Lockwood CJ. Preterm labor: clinical findings, diagnostic evaluation, and initial treatment. UpToDate. <a href="www.uptodate.com">www.uptodate.com</a>. Updated April 20, 2023. Accessed September 29, 2023.
- 17. National Diabetes Education Initiative staff. Diabetes Management Guidelines: Endocrine Society Guideline on Diabetes in Pregnancy. Published January 2016.
- 18. Norwitz ER. Preeclampsia: antepartum management and timing of delivery. UpToDate. <a href="https://www.uptodate.com">www.uptodate.com</a>. Updated August 4, 2023. Accessed September 29, 2023.



- 19. Signore C, Spong C. Overview of antepartum fetal assessment. UpToDate. www.uptodate.com. Updated July 24, 2023. Accessed September 29, 2023.
- 20. Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. *Obstet Gynecol*. 2009;113(3):687 to 701. doi:10.1097/AOG.0b013e318197bd8a
- 21. Smith JA, Fox KA, Clark S. Nausea and vomiting of pregnancy: treatment and outcome. UpToDate. <a href="www.uptodate.com">www.uptodate.com</a>. Updated July 14, 2023. Accessed September 29, 2023.
- 22. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. *Obstet Gynecol*. 2020;135(6):1492 to 1495. doi:10.1097/AOG.000000000003892
- 23. Norwitz ER. Progesterone supplementation to reduce the risk of spontaneous preterm birth. UpToDate. <a href="https://www.uptodate.com">www.uptodate.com</a>. Updated June 23, 2023. Accessed September 29, 2023.
- 24. ACOG Statement on 17p Hydroxyprogesterone Caproate. Accessed at: <a href="https://www.acog.org/news/news-releases/2019/10/acog-statement-on-17p-hydroxyprogesterone-caproate">https://www.acog.org/news/news-releases/2019/10/acog-statement-on-17p-hydroxyprogesterone-caproate</a> Published October 25, 2019. Accessed September 29, 2023.
- 25. The American College of Obstetricians and Gynecologists. Chronic Hypertension in Pregnancy Number 203. Accessed at: <a href="https://www.acog.org/-/media/project/acog/acogorg/clinical/files/practice-bulletin/articles/2019/01/chronic-hypertension-in-pregnancy.pdf">https://www.acog.org/-/media/project/acog/acogorg/clinical/files/practice-bulletin/articles/2019/01/chronic-hypertension-in-pregnancy.pdf</a>. Published January 2019. Accessed September 29,2023.
- 26. Petit C, Deruelle P, Behal H, et al. Preterm premature rupture of membranes: Which criteria contraindicate home care management? *Acta Obstet Gynecol Scand*. 2018;97(12):1499 to 1507. doi:10.1111/aogs.13433
- 27. Norwitz ER. Preeclampsia: intrapartum and postpartum management and long-term prognosis. UpToDate. <a href="www.uptodate.com">www.uptodate.com</a>. Updated May 12, 2023. Accessed September 29, 2023.
- 28. Simmons D. Paradigm Shifts in the Management of Diabetes in Pregnancy: The Importance of Type 2 Diabetes and Early Hyperglycemia in Pregnancy: The 2020 Norbert Freinkel Award Lecture. *Diabetes Care*. 2021;44(5):1075 to 1081. doi:10.2337/dci20-0055
- 29. Indications for Outpatient Antenatal Fetal Surveillance. www.acog.org. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/06/indications-for-outpatient-antenatal-fetal-surveillance

#### **Important reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,



contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.